Hikma Pharmaceuticals (LON:HIK) Shares Pass Above Two Hundred Day Moving Average - Here's Why

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s stock price passed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of GBX 2,014.14 ($26.81) and traded as high as GBX 2,040 ($27.15). Hikma Pharmaceuticals shares last traded at GBX 2,004 ($26.67), with a volume of 244,540 shares.

Wall Street Analysts Forecast Growth

HIK has been the topic of several research reports. JPMorgan Chase & Co. restated an "overweight" rating on shares of Hikma Pharmaceuticals in a report on Friday, March 7th. Berenberg Bank restated a "buy" rating and set a GBX 2,560 ($34.07) price target on shares of Hikma Pharmaceuticals in a research note on Monday, March 10th.

Hikma Pharmaceuticals Trading Down 0.4%

The stock has a market capitalization of £5.40 billion, a P/E ratio of 19.11, a P/E/G ratio of 2.38 and a beta of 0.41. The stock's 50 day moving average price is GBX 1,960.25 and its 200-day moving average price is GBX 2,014.51. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82.

Hikma Pharmaceuticals Increases Dividend

The business also recently announced a dividend, which was paid on Thursday, May 1st. Shareholders of record on Thursday, March 20th were given a dividend of $0.48 per share. This represents a yield of 1.8%. The ex-dividend date of this dividend was Thursday, March 20th. This is a boost from Hikma Pharmaceuticals's previous dividend of $0.32. Hikma Pharmaceuticals's dividend payout ratio (DPR) is 60.84%.

Insider Activity

In related news, insider Victoria Hull sold 2,777 shares of the business's stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of GBX 1,800 ($23.96), for a total transaction of £49,986 ($66,523.82). Company insiders own 30.54% of the company's stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly.